Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesLiposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Trends in Pharmacological Sciences, 10/29/09
Malam Y et al. – Nanoscale drug delivery systems using liposomes and nanoparticles are emerging technologies for the rational delivery of chemotherapeutic drugs in the treatment of cancer. Their use offers improved pharmacokinetic properties, controlled and sustained release of drugs and, more importantly, lower systemic toxicity. The commercial availability of liposomal Doxil and albumin–nanoparticle–based Abraxane® has focused attention on this innovative and exciting field. Recent advances in liposome technology offer better treatment of multidrug–resistant cancers and lower cardiotoxicity.
Related Articles
New Dual Mode Gadolinium Nanoparticle Contrast Agent for Magnetic Resonance Imaging
PLoS ONE - Cardiovascular Disorders, 11/13/09
Relevance Score: 87%
Ultrasound-Triggered Release of Recombinant Tissue-Type Plasminogen Activator from Echogenic Liposomes
Ultrasound in Medicine and Biology, 11/12/09
Relevance Score: 85%
Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes
International Braz J Urol, 11/06/09
Relevance Score: 84%
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B
Critical Care, 10/20/09
Relevance Score: 84%
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
Journal of Clinical Oncology, 10/30/09
Relevance Score: 82%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now
Supportive Care in Cancer, 03/18/10
Human genome sciences announces results of randomized phase 2 trial of mapatumumab in non-small cell lung cancer
Human Genome Sciences, 03/18/10
Metronomic chemotherapy in advanced soft tissue sarcomas
Cancer Chemotherapy and Pharmacology, 03/17/10
Article Search
Sponsor
Sponsor